tbuckley/cabot-search huggingface dataset:
Abstract 9477: Relation Between Coronary Artery Calcium Score and Clinical Outcomes After Percutaneous Coronary Intervention in Stable Coronary Artery Disease
Authors: Soichi Komaki, Masanobu Ishii, sou ikebe, Ryota Kaichi, Masafumi Takae, Takayuki Mori, Reiko Toida, Kazumasa Kurogi, Nobuyasu Yamamoto, Kenichi Tsujita, Koichi Kaikita
Journal: Circulation (2021)

Introduction: Recently, some consensus on high bleeding and thrombotic risk has been reported in the management of patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). However, none of the currently available risk scores includes coronary artery calcification (CAC) score. The usefulness of the assessment of coronary artery calcium on the net adverse clinical event (NACE) in patients with stable CAD undergoing PCI remains understudied. This study aimed to evaluate the association between the CAC score measured by multidetector computed tomography (MDCT) and clinical outcomes after percutaneous coronary intervention (PCI) in stable CAD patients. Methods: We conducted a retrospective observational study including 134 consecutive patients who underwent MDCT and were scheduled for the first elective PCI. The patients were divided into 2 groups based on the CAC score [low (≤ 400) and high (&gt; 400) CAC score]. High bleeding risk was assessed using the Academic Research Consortium for high bleeding risk (ARC-HBR) and the Japanese Circulation Society High Bleeding Risk (JCS-HBR) criteria. The clinical outcome was NACE that was defined as a composite of all-cause death, myocardial infarction (MI), stroke, target lesion revascularization (TLR), stent thrombosis, and major bleeding. According to the Bleeding Academic Research Consortium (BARC) definition, major bleeding was defined as BARC 3 and 5. Results: The high CAC score group was significantly associated with NACE than the low CAC group (22.0% vs 7.5%, P = 0.019). The Cox regression analyses showed that CAC score but not HBR-positive was a significant prognostic factor for NACE (HR, 3.27; 95% CI, 1.14-10.4; p &lt; 0.028, HR, 1.12; 95% CI, 0.37-3.21; p = 0.834, respectively). The Kaplan-Meier survival curves showed that the high CAC group had a higher frequency of NACE events compared with the low CAC group (p = 0.012). Conclusions: The association of high CAC score with NACE including thrombotic and bleeding events were observed in patients with stable CAD, indicating that high CAC was independently related to being a predictor for NACE after PCI.
Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Authors: Danielle S. Wallace, Andrea M. Baran, Jonathan W. Friedberg, Patrick M. Reagan, Carla Casulo, Mijamin Friend, Alyssa R. Williams, Peter D Dakin, Clive S. Zent, Paul M. Barr
Journal: Blood (2021)
Outcomes of Patients with Extended Anticoagulation Using Low Dose Doacs Compared to Standard Therapeutic Anticoagulation
Authors: Azza Ahmed, Ahmed Pasha, David O. Hodge, Ana I Casanegra, Lisa Peterson, Danielle Vlazny, Robert D. McBane, Waldemar Wysokinski, Damon E. Houghton
Journal: Blood (2021)
Functional screen of inflammatory bowel disease genes reveals key epithelial functions
Authors: Jessy Carol Ntunzwenimana, Gabrielle Boucher, Jean Paquette, Hugues Gosselin, Azadeh Alikashani, Nicolas Morin, Claudine Beauchamp, Louise Thauvette, Marie-Ève Rivard, Frédérique Dupuis, Sonia Deschênes, Sylvain Foisy, Frédéric Latour, Geneviève Lavallée, Mark J. Daly, Ramnik J. Xavier, Alain Bitton, Gabrielle Boucher, Guy Charron, Christine Des Rosiers, Anik Forest, Philippe Goyette, Sabine Ivison, Lawrence Joseph, Rita Kohen, Jean Lachaine, Sylvie Lesage, Megan K. Levings, John D. Rioux, Julie Thompson Legault, Luc Vachon, Sophie Veilleux, Brian White-Guay, Guy Charron, Philippe Goyette, John D. Rioux
Journal: Genome Medicine (2021)

Abstract Background Genetic studies have been tremendously successful in identifying genomic regions associated with a wide variety of phenotypes, although the success of these studies in identifying causal genes, their variants, and their functional impacts has been more limited. Methods We identified 145 genes from IBD-associated genomic loci having endogenous expression within the intestinal epithelial cell compartment. We evaluated the impact of lentiviral transfer of the open reading frame (ORF) of these IBD genes into the HT-29 intestinal epithelial cell line via transcriptomic analyses. By comparing the genes in which expression was modulated by each ORF, as well as the functions enriched within these gene lists, we identified ORFs with shared impacts and their putative disease-relevant biological functions . Results Analysis of the transcriptomic data for cell lines expressing the ORFs for known causal genes such as HNF4a, IFIH1, and SMAD3 identified functions consistent with what is already known for these genes. These analyses also identified two major clusters of genes: Cluster 1 contained the known IBD causal genes IFIH1, SBNO2, NFKB1, and NOD2, as well as genes from other IBD loci (ZFP36L1, IRF1, GIGYF1, OTUD3, AIRE and PITX1), whereas Cluster 2 contained the known causal gene KSR1 and implicated DUSP16 from another IBD locus. Our analyses highlight how multiple IBD gene candidates can impact on epithelial structure and function, including the protection of the mucosa from intestinal microbiota, and demonstrate that DUSP16 acts a regulator of MAPK activity and contributes to mucosal defense, in part via its regulation of the polymeric immunoglobulin receptor, involved in the protection of the intestinal mucosa from enteric microbiota. Conclusions This functional screen, based on expressing IBD genes within an appropriate cellular context, in this instance intestinal epithelial cells, resulted in changes to the cell’s transcriptome that are relevant to their endogenous biological function(s). This not only helped in identifying likely causal genes within genetic loci but also provided insight into their biological functions. Furthermore, this work has highlighted the central role of intestinal epithelial cells in IBD pathophysiology, providing a scientific rationale for a drug development strategy that targets epithelial functions in addition to the current therapies targeting immune functions.
High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Authors: Andrew H. Lipsky, Brian T. Hill, Allison M. Winter, Joseph G. Jurcic, Mark L. Heaney, Todd L. Rosenblat, Matthew Chiaramonte, Hanna Weissbrot, Nicole Lamanna
Journal: Blood (2021)
Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity
Authors: Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, Tyler Lowe, David F. Stroncek, Steven Highfill, Rashmika Patel, Micaela Ganadan, Steven A Rosenberg, James N. Kochenderfer
Journal: Blood (2021)
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
Authors: Benedikt Schoser, Mark Roberts, Barry J Byrne, Sheela Sitaraman, Hai Jiang, Pascal Laforêt, Antonio Toscano, Jeff Castelli, Jordi Díaz-Manera, Mitchell Goldman, Ans T van der Ploeg, Drago Bratkovic, Srilakshmi Kuchipudi, Tahseen Mozaffar, Priya S Kishnani, Agnes Sebok, Alan Pestronk, Aleksandra Dominovic-Kovacevic, Aneal Khan, Blaž Koritnik, Celine Tard, Christopher Lindberg, Colin Quinn, Cornelia Kornblum, Crystal Eldridge, Cynthia Bodkin, David Reyes-Leiva, Derralynn Hughes, Ela Stefanescu, Emmanuelle SALORT-CAMPANA, Ernest Butler, Francoise Bouhour, Gee Kim, George Konstantinos Papadimas, Giancarlo Parenti, Halina Bartosik-Psujek, Hani Kushlaf, Hashiguchi Akihiro, Heather Lau, Helio Pedro, Henning Andersen, Hernan Amartino, Hideaki Shiraishi, Hiroshi Kobayashi, Ivaylo Tarnev, Jaime Vengoechea, Jennifer Avelar, Jin-Hong Shin, Jonathan Cauci, Jorge Alonso-Pérez, Jozsef Janszky, Julie Berthy, Kristina Gutschmidt, Kristl Claeys, Maria Judit Molnar, Marie Wencel, Mark Tarnopolsky, Mazen Dimachkie, Michel Tchan, Miriam Freimer, Nicola Longo, Nuria Vidal-Fernandez, Olimpia Musumeci, Ozlem Goker-Alpan, Patrick Deegan, Paula R. Clemens, Richard Roxburgh, Robert Henderson, Robert Hopkin, Sabrina Sacconi, Simona Fecarotta, Shahram Attarian, Stephan Wenninger, Stephanie Dearmey, Tarekegn Hiwot, Thomas Burrow, Tobias Ruck, Tomo Sawada, Vescei Laszlo, Wolfgang Löscher, Yin-Hsiu Chien
Journal: The Lancet Neurology (2021)
Abstract 9033: Effectiveness of a Virtual Patient Simulation at Improving Management of Complex Patients with Arterial Disease
Authors: Margaret Harris, Jelena Spyropoulos, Michael Lacouture, Allison Armagan, Catherine Capparelli, Mahira Bonomo
Journal: Circulation (2021)

Introduction: Despite evidence and guidelines for management of patients with arterial disease, including CAD and PAD, patients remain at high risk for adverse cardiac events. Cardiologists are challenged to implement the latest evidence-based strategies to reduce risk for adverse cardiovascular events in these patients. We sought to determine if an online, virtual patient simulation (VPS)-based continuing medical education intervention could improve performance of cardiologists related to implementation of effective antithrombotic strategies to improvement management of patients with CAD and PAD. Methods: The intervention comprised two patients presenting in a VPS platform that allows learners to order lab tests, make diagnoses, and prescribe treatments in a manner matching the scope and depth of actual practice. Tailored clinical guidance (CG), based on current evidence and expert recommendation, was provided following each decision, followed by the opportunity for the learner to modify their decisions. Decisions were collected post-CG and compared with each user’s baseline (pre-CG) decisions using a McNemar’s test to determine P values. Data were collected July 30-November 10, 2020. Results: Significant absolute improvements were observed after CG for the following: Case 1 (n= 152) Order/Initiate: Screening for high-risk categorization using modified REACH score: 15% improvement (24% pre-CG vs 39% post-CG; P&lt;.001); Evaluate for bleeding risk: 20% improvement (25% pre-CG vs 46% post-CG; P&lt;.001); Rivaroxaban: 55% improvement (0% pre-CG vs 55% post-CG; P&lt;.001); Continue aspirin: 1% improvement (86% pre-CG vs 87% post-CG, P=ns); Follow-up visits: 14% improvement (41% pre-CG vs 55% post-CG; P&lt;.001) Case 2 (n= 113) Order/Initiate: ABI: 44% improvement (1% pre-CG vs 45% post-CG; P&lt;.001); Rivaroxaban: 55% improvement (0% pre-CG vs 55% post-CG; P&lt;.001); Continue aspirin: 7% improvement (81% pre-CG vs 88% post-CG, P&lt;.05); Follow-up visits: 17% improvement (50% pre-CG vs 67% post-CG; P&lt;.001) Conclusions: VPS that immerses and engages specialists in an authentic, patient-based, practical learning environment can significantly improve evidence-based clinical decision making for the management of complex arterial disease.
Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes
Authors: Sanjay De Mel, Jonathan Adam Scolnick, Chern Han Yong, Xiaojing Huo, Stacy Xu, Cinnie Yentia Soekojo, Fangfang Song, Melissa Ooi, Wee Joo Chng
Journal: Blood (2021)
Reticular Dysgenesis-Associated Adenylate Kinase 2 Deficiency Impairs Purine Metabolism and Ribosomal Biogenesis during Myelopoiesis
Authors: Wenqing Wang, Andrew Devilbiss, Martin Arreola, Thomas Mathews, Misty Martin-Sandoval, Zhiyu Zhao, Avni Awani, Daniel P. Dever, Matthew H. Porteus, Sean Morrison, Katja G Weinacht
Journal: Blood (2021)
Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy
Authors: Anne Niezink, Jaap van Doesum, Max Beijert, Marcel Nijland, Hans Langendijk, Dianne Busz, Anne P.G. Crijns, Gerwin A. Huls, Tom Van Meerten
Journal: Blood (2021)
Adherence Trajectories of Extended Direct-Acting Oral Anticoagulants and Risk of Recurrent Venous Thromboembolism and Major Bleeding: A Retrospective Cohort Study
Authors: Hye-Rim Kang, Bobby L Jones, Wei-Hsuan Lo-Ciganic, Christina E DeRemer, Eric A Dietrich, Pei-Lin Huang, Martina C Murphy, Haesuk Park
Journal: Blood (2021)
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
Authors: Tianyang Mao, Benjamin Israelow, Carolina Lucas, Chantal B.F. Vogels, Maria Luisa Gomez-Calvo, Olga Fedorova, Mallery I. Breban, Bridget L. Menasche, Huiping Dong, Melissa Linehan, Tara Alpert, F. Brito Anderson, Rebecca Earnest, Joseph R. Fauver, Chaney C. Kalinich, Ketty Munyenyembe, Isabel M. Ott, Mary E. Petrone, Jessica Rothman, Anne E. Watkins, Craig B. Wilen, Marie L. Landry, Nathan D. Grubaugh, Anna M. Pyle, Akiko Iwasaki
Journal: The Journal of Experimental Medicine (2021)

As SARS-CoV-2 continues to cause morbidity and mortality around the world, there is an urgent need for the development of effective medical countermeasures. Here, we assessed the antiviral capacity of a minimal RIG-I agonist, stem-loop RNA 14 (SLR14), in viral control, disease prevention, post-infection therapy, and cross-variant protection in mouse models of SARS-CoV-2 infection. A single dose of SLR14 prevented viral infection in the lower respiratory tract and development of severe disease in a type I interferon (IFN-I)–dependent manner. SLR14 demonstrated remarkable prophylactic protective capacity against lethal SARS-CoV-2 infection and retained considerable efficacy as a therapeutic agent. In immunodeficient mice carrying chronic SARS-CoV-2 infection, SLR14 elicited near-sterilizing innate immunity in the absence of the adaptive immune system. In the context of infection with variants of concern (VOCs), SLR14 conferred broad protection against emerging VOCs. These findings demonstrate the therapeutic potential of SLR14 as a host-directed, broad-spectrum antiviral for early post-exposure treatment and treatment of chronically infected immunosuppressed patients.
Comparison of Clinical Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel in the Elara Trial Versus a Real-World External Control Arm of Patients Treated with Standard of Care
Authors: Yanni Hao, Wei-Chun Hsu, Craig S Parzynski, C Lobetti Bodoni, Evgeny Degtyarev, Lisa Hampson, Aisha Masood, Wen-Hsing Wu
Journal: Blood (2021)
Tinnitus prevalence in Europe: a multi-country cross-sectional population study
Authors: R. Biswas, A. Lugo, M.A. Akeroyd, W. Schlee, S. Gallus, D.A. Hall
Journal: The Lancet Regional Health - Europe (2021)

Tinnitus prevalence studies report large variability across countries that might be due to inconsistent research methods. Our study aimed to report a single Pan-European estimate for tinnitus prevalence and investigate the effect of individual and country-level characteristics on prevalence. We explored the relationships of healthcare resource use and hearing difficulty with tinnitus symptoms.Between 2017-2018, a cross-sectional European Tinnitus Survey (ETS) was conducted in 12 European Union nations (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania, and Spain), using a standardised set of tinnitus-related questions and response options in country-specific languages. We recruited 11,427 adults aged ≥18 years.Prevalence of any tinnitus was 14·7% (14·0% in men and 15·2% in women), ranging from 8·7% in Ireland to 28·3% in Bulgaria. Severe tinnitus was found in 1·2% participants (1·0% in men and 1·4% in women), ranging from 0·6% in Ireland to 4·2% in Romania. Tinnitus prevalence significantly increased with increasing age and worsening of hearing status. Healthcare resource use for tinnitus increased with increasing tinnitus symptom severity.This is the first multinational report of Pan-European tinnitus prevalence using standardised questions. The overall prevalence estimates refine previous findings, although widespread inter-country heterogeneity was noted. The results indicate that more than 1 in 7 adults in the EU have tinnitus. Extrapolating to the overall population, approximately 65 million adults in EU28 have tinnitus, 26 million have bothersome tinnitus and 4 million have severe tinnitus.National Institute for Health Research, European Union's Horizon 2020, Medical Research Council, and GENDER-Net Co-Plus Fund.
Abstract 9146: Efficacy and Safety of Esaxerenone in Hypertensive Patients with Heart Failure with Reduced Ejection Fraction
Authors: Ryohei Ono, Togo Iwahana, Hirotoshi Kato, Sho Okada, Yoshio Kobayashi
Journal: Circulation (2021)

Introduction: Esaxerenone, a mineralocorticoid receptor blocker (MRB), is a new antihypertensive agent. However, esaxerenone-related data with respect to hypertension with heart failure are limited. Hypothesis: Esaxerenone is safe and effective for hypertensive patients with heart failure with reduced ejection fraction (HFrEF). Methods: Hypertensive patients with HFrEF treated with esaxerenone were retrospectively analyzed at two timepoints (short-term: 35±15 days; mid-term: 167±45 days) for hyperkalemia (K + &gt;5.5 mEq/L), worsening renal function (WRF; estimated glomerular filtration rate (eGFR) reduction by &gt;20%), and hypotension (systolic blood pressure &lt;90 mmHg) along with brain natriuretic peptide (BNP) level. Patients administered esaxerenone as their first MRB (first-MRB cohort, n=20) and those who converted from another MRB (conversion cohort, n=30) were separately analyzed as sub analysis. Results: Fifty patients (56±10 years old, 37 males) were enrolled in this study. At the short-term assessment, hyperkalemia or hypotension was not observed at a dose of 2.0±0.9 mg/day. Seven patients (14%) showed WRF. K + and serum creatinine (Cre) were elevated (4.12±0.41 to 4.25±0.39 mmol/L, p =0.07, and 0.95±0.34 to 1.01±0.34 mg/dL, p =0.01, respectively), and eGFR was significantly reduced (66.9±19.6 to 62.4±19.7 mL/min/1.73 m 2 , p =0.006). At the mid-term assessment, there were no significant changes regarding K + , Cre and eGFR compared to those at the short-term. BNP levels were consistently lowered at the short-term and mid-term assessment. Sub analysis at the short-term assessment showed the changes in K + , Cre, and eGFR were significant in the first-MRB cohort, while they were not significant in the conversion cohort. Conclusions: Esaxerenone was safe for hypertensive patients with HFrEF. Hyperkalemia and hypotension were rarely noted while eGFR was significantly reduced. Moreover, esaxerenone was effective for HFrEF with respect to BNP levels.
Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Authors: Alice S. Mims, Melhem Solh, Jennifer N. Saultz, Uma Borate, Naveen Pemmaraju, Gautam Borthakur, Gail J. Roboz, Ben Powell, Bernice Matusow, Jason Halladay, Shireen Vali, Chelsea L. Hope, Madan G. Kundu, Ching Hsu, Paul Watkins, Chao Zhang, Jackie M. Walling, Athanasios C. Tsiatis, Amy E. DeZern
Journal: Blood (2021)
Xanthine Oxidoreductase Inhibitors Suppress the Onset of Exercise-Induced AKI in High HPRT Activity Urat1-Uox Double Knockout Mice
Authors: Takuji Hosoya, Shunya Uchida, Shigeru Shibata, Naoko H. Tomioka, Koji Matsumoto, Makoto Hosoyamada
Journal: Journal of the American Society of Nephrology (2021)

Hereditary renal hypouricemia type 1 (RHUC1) is caused by URAT1/SLC22A12 dysfunction, resulting in urolithiasis and exercise-induced AKI (EIAKI). However, because there is no useful experimental RHUC1 animal model, the precise pathophysiologic mechanisms underlying EIAKI have yet to be elucidated. We established a high HPRT activity Urat1-Uox double knockout (DKO) mouse as a novel RHUC1 animal model for investigating the cause of EIAKI and the potential therapeutic effect of xanthine oxidoreductase inhibitors (XOIs).The novel Urat1-Uox DKO mice were used in a forced swimming test as loading exercise to explore the onset mechanism of EIAKI and evaluate related purine metabolism and renal injury parameters.Urat1-Uox DKO mice had uricosuric effects and elevated levels of plasma creatinine and BUN as renal injury markers, and decreased creatinine clearance observed in a forced swimming test. In addition, Urat1-Uox DKO mice had increased NLRP3 inflammasome activity and downregulated levels of Na+-K+-ATPase protein in the kidney, as Western blot analysis showed. Finally, we demonstrated that topiroxostat and allopurinol, XOIs, improved renal injury and functional parameters of EIAKI.Urat1-Uox DKO mice are a useful experimental animal model for human RHUC1. The pathogenic mechanism of EIAKI was found to be due to increased levels of IL-1β via NLRP3 inflammasome signaling and Na+-K+-ATPase dysfunction associated with excessive urinary urate excretion. In addition, XOIs appear to be a promising therapeutic agent for the treatment of EIAKI.
<i>Thiol Isomerase Activity of</i> <i>β</i> <i>3 Integrin Psi Domain and L33P Polymorphism: Implications in Blood Coagulation and Anti-Thrombotic Therapy</i>
Authors: Eric Gaetano Cerenzia, Tyler W. Stratton, Daniel Mackeigan, Zhenze Liu, Guangheng Zhu, Xi Lei, Preeti Bhoria, Heyu Ni
Journal: Blood (2021)
Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Authors: Sushree S. Sahoo, Victor B. Pastor, Charnise Goodings, Rebecca K. Voss, Emilia J. Kozyra, Amina Szvetnik, Peter Noellke, Michael Dworzak, Jan Starý, Franco Locatelli, Riccardo Masetti, Markus Schmugge, Barbara De Moerloose, Albert Catala, Krisztián Kállay, Dominik Turkiewicz, Henrik Hasle, Jochen Buechner, Kirsi Jahnukainen, Marek Ussowicz, Sophia Polychronopoulou, Owen P. Smith, Oksana Fabri, Shlomit Barzilai, Valerie de Haas, Irith Baumann, Stephan Schwarz-Furlan, Jan Starý, Barbara De Moerloose, Krisztián Kallay, Owen Smith, Valérie De Haas, Gudrun Gohring, Charlotte Niemeyer, Karin Nebral, Ingrid Simonitsch-Kluppp, Pascale De Paepe, Nadine Van Roy, Vit Campr, Zuzana Zemanova, Erik Clasen-Linde, Tine Plesner, Brigitte Schlegelberger, Martina Rudelius, Kalliopi Manola, Kalliopi Stefanaki, Judit Csomor, Hajnalka Andrikovics, David Betts, Maureen O’Sullivan, Yaniv Zohar, Marta Jeison, Rita De Vito, Francesco Pasquali, Jadwiga Maldyk, Olga Haus, Helena Alaiz, Paula Kjollerstrom, Luis Mascarenhas de Lemos, Ivana Bodova, Martin Čermák, Lukas Plank, Barbara Gazic, Marko Kavcic, Helena Podgornik, Margarita Llavador Ros, Jose Cervera, Carole Gengler, Joelle Tchinda, Berna Beverloo, Roos Leguit, Marena R. Niewisch, Martin G. Sauer, Birgit Burkhardt, Peter Lang, Peter Bader, Rita Beier, Ingo Müller, Michael H. Albert, Roland Meisel, Ansgar Schulz, Gunnar Cario, Pritam K. Panda, Julius Wehrle, Shinsuke Hirabayashi, Marta Derecka, Robert Durruthy-Durruthy, Gudrun Göhring, Ayami Yoshimi-Noellke, Manching Ku, Dirk Lebrecht, Miriam Erlacher, Christian Flotho, Brigitte Strahm, Charlotte M. Niemeyer, Marcin W. Wlodarski
Journal: Nature Medicine (2021)
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Authors: Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren Pinter-Brown, Francine Foss, Larisa Geskin, Lawrence Schwartz, Steven Horwitz, Joan Guitart, John Zic, Youn H. Kim, Gary S. Wood, Madeleine Duvic, Wei Ai, Michael Girardi, Alejandro Gru, Emmanuella Guenova, Emmilia Hodak, Richard Hoppe, Werner Kempf, Ellen Kim, Mary Jo Lechowicz, Pablo Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Mark Pittelkow, H. Miles Prince, Jose Antonio Sanches, Makoto Sugaya, Maarten Vermeer, Jasmine Zain, Robert Knobler, Rudolf Stadler, Martine Bagot, Julia Scarisbrick
Journal: Blood (2021)